Navigation Links
MGI Pharma Summarizes Data Presented at the 2007 American Society,of Clinical Oncology (ASCO) Annual Meeting

al and repeat courses of moderately and highly emetogenic cancer chemotherapy and for the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Aloxi is the first and only

5-HT3 receptor antagonist to be indicated for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) caused by moderately emetogenic cancer chemotherapy. In clinical trials, the most common adverse reactions related to Aloxi were headache (9%) and constipation (5%). Aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. Please see the Aloxi package insert, available at www.mgipharma.com and www.aloxi.com, for important additional details.

About Dacogen(R) For Injection

Dacogen is approved by the U.S Food and Drug Administration for the treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System

(IPSS) groups. Dacogen may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen. Men should be advised not to father a child while receiving treatment with Dacogen and for 2 months afterwards. In clinical trials, the most commonly occurring adverse reactions included neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%). Pl
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:4/25/2015)... 25. April 2015 Hospira, Inc. ... der Entwicklung von Biosimilar-Behandlungen, sprach heute auf der ... Generikaverbands (EGA) in London ... der Verfügbarkeit von Biosimilars für Patienten. ... White Papers mit dem Titel „Why extrapolation ...
(Date:4/24/2015)... 24, 2015  Perrigo Company plc ("Perrigo" or the ... the unsolicited offer from Mylan NV ("Mylan") (NASDAQ: ... of Perrigo for $60.00 per share in cash and ... (the "Offer").  The Board previously concluded ... undervalued the Company and its future growth prospects and ...
(Date:4/24/2015)... N.C. , April 24, 2015  New ... ability of consumers to educate themselves about products ... the tools and techniques available to market researchers ... the changing consumer marketplace, it,s imperative that organizations ... to better identify market opportunities, niches and growth ...
Breaking Medicine Technology:Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8Perrigo Rejects Mylan Unsolicited Offer 2Perrigo Rejects Mylan Unsolicited Offer 3Perrigo Rejects Mylan Unsolicited Offer 4Pharmaceutical Industry Using New Technologies to Adjust Their Marketing and Research Approaches for Consumers 2
... April 18, 2012  CAQH® announced today that ... the Universal Provider Datasource® (UPD®), demonstrating that ... standard for self-reported provider data used to ... network directories, referrals and claims administration. ...
... Live has revealed further details of the newest event ... (SEA) 2012. Set to debut from 10-12 May 2012 at ... first trade show and exhibition of its kind to be ... CPhI SEA will provide a meeting place ...
Cached Medicine Technology:One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 2One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... Review, H1 2015” provides comparative analysis on ... The report strengthens R&D pipelines by identifying ... and best-in-class products. Complete report on H1 ... 26 market data tables and 14 figures, ...
(Date:4/27/2015)... 2015 The Radiology Business Management ... with applied business information and intelligence, is proud to ... email newsletter for its more than 2,000 members. , ... legislative news sources in that it is exclusively devoted ... of radiology. The newsletter is produced in cooperation with ...
(Date:4/27/2015)... Final Cut Pro X users can ... Pixel Film Studios. A telestrator is a device that allows ... or still video image. Telestrators are often used in sports ... incoming weather patterns. , After users are done drawing,users can ... slider to control the speed of the animation. This can ...
(Date:4/27/2015)... April 27, 2015 PREVENT Life Safety, ... its Texas operations with the addition of an account ... safety services to a growing customer base, Curtis Rice, ... a new Senior Account Manager. Curtis has been added ... existing customers throughout the Houston area and beyond. ...
(Date:4/27/2015)... Hills, California (PRWEB) April 27, 2015 ... and former Amazon engineer, ZendyBeauty offered consumers a ... cosmetic providers at affordable prices. Using a patent-pending ... appointments for standard procedures like Botox®, laser hair ... doctors and their staff had gaps in their ...
Breaking Medicine News(10 mins):Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Essential Thrombocythemia Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2Health News:Pixel Film Studios releases ProTelestrator for Final Cut Pro X. 2Health News:PREVENT Life Safety Services Welcomes Curtis Rice as a New Senior Account Manager in Houston, TX 2Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2
... SAN FRANCISCO, Jan. 6 The American Asthma Foundation,announced ... dust mites are a major source of airborne allergens ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090106/AQTU532 ) , ... Foundation, explains,that "although dust mites are known to trigger ...
... (OTC Bulletin Board: SCIE), a San Diego based ... been awarded U.S. Patent number 7,469,160 for its ... Hitchin, SpectraScience,s CEO, commented, "This patent is another ... The invention provides methods of focusing an instrument ...
... Combines Retinoid and Benzoyl Peroxide in a Single ... Texas, Jan. 6 Galderma Laboratories, L.P. today ... peroxide) Gel 0.1% / 2.5%, the first and ... well-tolerated retinoid adapalene, and benzoyl peroxide, a well-known ...
... ABBOTT PARK, Ill., Jan. 6 Isis Pharmaceuticals, Inc. (Nasdaq: ... ) announced today that Abbott has completed its purchase of ... price of $175 million. In addition to the closing ... tied to post-closing sales of Ibis systems, including instruments and ...
... VILLAGE, Calif., Jan. 6 Specialists On Call, ... the states in which it provides service, including ... provider of emergency neurology on-call services to hospitals, ... consultations to date.(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/LAW515LOGO )Dr. Joe ...
... Specialists On Call, Inc. (SOC) announced ... business development staff to address the accelerating demand ... largest provider of emergency neurology on-call services to ... neurology consultations to date.(Logo: http://www.newscom.com/cgi-bin/prnh/20081022/LAW515LOGO )Dr. ...
Cached Medicine News:Health News:American Asthma Foundation Announces Breakthrough Discovery 2Health News:American Asthma Foundation Announces Breakthrough Discovery 3Health News:SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus 2Health News:SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus 3Health News:Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne 2Health News:Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne 3Health News:Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne 4Health News:Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis 2Health News:Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis 3Health News:Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis 4Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in North Carolina 2Health News:Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Florida 2
... Mouthpiece 7FT O 2 Tubing Tee Adapter, ... for fast treatment times , ... (higher percentage of respirable particles) than conventional nebulizers, ... Max 10™ disposable nebulizers deliver fast and effective ...
Nebulizer Custom Kit...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... Products, ,Westmed designs, manufacturers and markets ... Respiratory professionals. Our mission is to design ... ability to deliver quality medical care while ... , ,Our web site is designed ...
Medicine Products: